Opinion/Ideas: Biotech Buyout Watchlist for 2019
The excitement of merger and acquisition is back on for the biotechnology sector. With two buyouts from the back-to-back week of the 2019 year, one was from last week when Bristol Myers Squibb Co (BMY) acquired Celgene Corporation (CELG) for $74 billion, then this week Eli Lilly and Co (LLY) acquired Loxo Oncology Inc (LOXO) for $8 billion. In case you missed last year ideas/opinion buyout, (LOXO) was on the list. https://www.tradersfish.com/blog/ideasopinions-the-next-biotech-buyout
This led us to share our opinion/ideas for the 2019 year speculation buyout. This is only to be view as opinion/ideas only, you should do your own due diligence before investing in biotech. Here are the top list on our watchlist for the 2019 year.
Furthermore, the biotech clinical data update is big mover like today SAGE Therapeutics Inc (SAGE), and Axsome Therapeutics Inc (AXSM) both are up 42.68% and 161.22%, respectively. For biotech enthusiast that look for biotech clinical data for 1Q 2019, our link is here https://www.tradersfish.com/Biotechnology_formula/upcomingdata
For risk mitigation, use our site #BiotechCalculation it has over 80% accuracy predicting clinical data results. https://www.tradersfish.com/Biotechnology_formula
Disclaimer: I (we) do not hold any positions from stocks mentioned above. This is opinion and ideas only. Not to be used as investment advice. Always do your own due diligence and we are not responsible for any trade losses.